1 / 8

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report identifies the key trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market.

aarkresearch
Download Presentation

Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers.

  2. Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 • Date: 20 February 2012 • Pages: 81 • SummaryChemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report identifies the key trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chemotherapy induced Nausea and Vomiting Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.ScopeThe report provides information on the key drivers and challenges of the Chemotherapy induced Nausea and Vomiting Therapeutics market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chemotherapy induced Nausea and Vomiting Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.- Analysis of the current and future competition in the seven key countries Chemotherapy induced Nausea and Vomiting Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chemotherapy induced Nausea and Vomiting Therapeutics market.- Analysis of key recent licensing and partnership agreements in Chemotherapy induced Nausea and Vomiting Therapeutics market

  3. Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Reasons to buyThe report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Chemotherapy induced Nausea and Vomiting Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chemotherapy induced Nausea and Vomiting Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global Chemotherapy induced Nausea and Vomiting Therapeutics market landscape? – Identify, understand and capitalize.

  4. 1.1 List of Tables 41.2 List of Figures 52 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Introduction 72.1 Overview 72.1.1 Classification of Chemotherapy-Induced Nausea and Vomiting 72.2 Risk factors for Chemotherapy-Induced Nausea and Vomiting 82.3 Epidemiology 102.4 Symptoms 102.5 Etiology 102.6 Pathophysiology 112.7 Diagnosis 132.8 Treatment of Chemotherapy-Induced Nausea and Vomiting 132.8.1 Current Guidelines 132.8.2 Prevention of CINV by Emetogenic Potential of Chemotherapy and Class 202.9 GlobalData Pipeline Report Guidance 223 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Market Characterization 233.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Global 233.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Global 253.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - the US 273.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - the US 283.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - France 293.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - France 303.7 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Germany 313.8 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Germany 323.9 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Italy 333.10 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Italy 343.11 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Spain 353.12 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Spain 363.13 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - the UK 373.14 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - the UK 383.15 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Size (2006-2011) - Japan 393.16 Chemotherapy-Induced Nausea and Vomiting Therapeutics Market Forecast (2011-2019) - Japan 403.17 Drivers and Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 413.17.1 Drivers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 41

  5. 3.17.2 Barriers for the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 413.18 Key Events Impacting the Future Market 423.19 Opportunity and Unmet Need Analysis 423.19.1 Key Takeaway 434 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Competitive Assessment 444.1 Overview 444.2 Strategic Competitor Assessment 444.3 Product Profile for the Major Marketed Products in the Chemotherapy-Induced Nausea and Vomiting Therapeutics Market 454.3.1 Anzemet (dolasetronmesylate) 454.3.2 Kytril (granisetron) 464.3.3 Sancuso (granisetron Transdermal System) 474.3.4 Zuplenz/Zofran (ondansetron) 484.3.5 Aloxi (palonosetron hydrochloride) 494.3.6 Emend (aprepitant/fosaprepitantdimeglumine) 504.4 Key Takeaway 525 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment 535.1 Overview 535.2 Strategic Pipeline Assessment 535.3 Chemotherapy-Induced Nausea and Vomiting Pipeline - Pipeline by Phases of Development 535.3.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pre-registration Pipeline 545.3.2 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase III Pipeline 545.3.3 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase II Pipeline 545.3.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Phase I Pipeline 545.3.5 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Preclinical 555.3.6 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Discovery 555.4 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Pipeline by Mechanism of Action 555.5 Chemotherapy-Induced Nausea and Vomiting Technology Trends Analytical Framework 565.6 Molecule Profile for Key Late Stage Drugs under Clinical Development 575.6.1 APF530 575.6.2 EUR-1025 585.6.3 Netupitant 585.7 Key takeaway 58

  6. 6 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Clinical Trials Mapping 596.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 596.2 Clinical Trials Mapping by Phase 606.3 Clinical Trials Mapping by Trial Status 616.4 Overall Sponsors 626.5 Prominent Sponsors 636.6 Top Companies Participating in Chemotherapy-Induced Nausea and Vomiting Therapeutics Clinical Trials 647 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Strategic Assessment 657.1 Chemotherapy-Induced Nausea and Vomiting Therapeutics - Implications for Future Market Competition 658 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Future Players 668.1 Introduction 668.2 Company Profiles 668.2.1 A.P. Pharma Inc. 668.2.2 AptalisPharma, Inc. 688.2.3 Eisai Co. Ltd 698.2.4 Helsinn Healthcare S.A. 719 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Licensing and Partnership Deals 7210 Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Appendix 7410.1 Definitions 7410.2 Acronyms 7410.3 Research Methodology 7510.3.1 Coverage 7510.3.2 Secondary Research 7610.3.3 Forecasting 7610.3.4 Primary Research 7810.3.5 Expert Panel Validation 7910.4 Contact Us 7910.5 Disclaimer 7910.6 Bibliography 79

  7. For more information, please visit: • http://www.aarkstore.com/reports/Chemotherapy-Induced-Nausea-and-Vomiting-CINV-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019-191434.htmlOr email us at contact@aarkstore.com or call +919272852585 • Related Reports • Vemurafenib - Comprehensive patent searchColesevelam - Comprehensive patent searchRifaximin - Comprehensive patent searchNevirapine - Comprehensive patent searchLiraglutide - Comprehensive patent searchVilazodone - Comprehensive patent searchHexylaminolevulinic Acid - Comprehensive patent searchTreprostinil - Comprehensive patent searchPatient Adherence, Communication and Engagement (PACE) - Increased Investment and Adoption of New Digital Tools Enable Key Stakeholder Collaborations and Encourage ComplianceExpress Scripts, Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT and Financial Report

  8. Contact Us Aarkstore Enterprise Tel : +912227453309 Mobile No:+08149852585 Email : contact@aarkstore.com Website : http://www.aarkstore.com Blog: http://www.emarketreports.com http://teju-aarkstoreenterprise.blogspot.in Follow us on twitter: http://twitter.com/aarkstoredotcom http://in.linkedin.com/in/aarkstore http://www.facebook.com/aarkstoreenterprise

More Related